First-Trimester Loss With a Prior Second-Trimester Loss: When to Escalate the RPL Workup
A 32-year-old G3P0 presents with her third pregnancy loss. First pregnancy: missed miscarriage at 9 weeks (no karyotype). Second pregnancy: preterm premature rupture of membranes and delivery at 19 weeks with a structurally normal fetus on autopsy. Third pregnancy: embryonic demise at 8 weeks; products of conception sent for genetic testing, which returns a normal female karyotype (46,XX) - raising the question of maternal cell contamination. She has regular cycles, no known thrombophilia, no hypertension, and a normal HbA1c. She asks what testing she needs and whether she should start aspirin and heparin with the next pregnancy.
1. Assess whether she meets criteria for recurrent pregnancy loss and interpret the 46,XX result on products of conception.
Read the worked answer
She meets the ASRM definition of recurrent pregnancy loss (two or more failed clinical pregnancies), with losses spanning first and second trimester. The second-trimester loss at 19 weeks with PPROM and a structurally normal fetus is a red flag for cervical insufficiency, uterine anomaly, or infection, and should not be lumped with first-trimester losses.
The 46,XX POC result is ambiguous. A female karyotype from products of conception can represent either a true female conceptus or maternal cell contamination (decidua). Without short tandem repeat (STR) genotyping or comparative genomic hybridization to distinguish maternal from fetal origin, the result cannot be used to exclude a fetal chromosomal cause. The appropriate next step is maternal buccal swab and STR comparison, or repeat testing with a method that can assess maternal contribution. If the result is confirmed maternal, the loss remains unexplained and a fetal chromosomal cause is not excluded.
Judgment point: Do not accept a 46,XX POC result at face value in a woman with recurrent loss.
2. Outline the RPL evaluation and justify whether empiric aspirin and heparin are appropriate.
Read the worked answer
Evaluation (ASRM/ACOG-aligned):
- Antiphospholipid antibody panel (lupus anticoagulant, anticardiolipin, anti-beta-2 glycoprotein I), repeated after 12 weeks if positive - the only thrombophilia with proven treatment benefit in RPL.
- Parental karyotypes - balanced translocation carrier status, especially given recurrent loss and a possible fetal chromosomal cause.
- Uterine evaluation - saline sonogram or hysteroscopy to assess for septum, adhesions, or anomaly; relevant given the second-trimester loss.
- Cervical assessment - history-indicated cerclage discussion for the 19-week loss pattern.
- Thyroid function and glucose screening - already normal.
- Consider inherited thrombophilia testing only in the context of a personal/family history of thrombosis - not routinely for RPL.
Aspirin and heparin: Empiric anticoagulation is not indicated absent antiphospholipid syndrome or a diagnosed thrombophilia. In APS, low-dose aspirin plus prophylactic heparin is standard. Outside APS, trials (e.g., ALIFE, SPIN) did not show benefit, and heparin carries bleeding and HIT risk.
Plan: Complete the APS panel and parental karyotypes; if negative, manage the next pregnancy with close surveillance, consider cerclage for the second-trimester history, and avoid empiric anticoagulation. If APS is confirmed, treat accordingly.
The tested skill is matching therapy to a confirmed diagnosis rather than to the emotional pressure of recurrent loss.